Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 23, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-01-22$65.00/sh−1,607$104,449→ 65,836 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/19/2024.